...
首页> 外文期刊>European urology >Predictors of Cancer-specific Mortality After Disease Recurrence in Patients with Squamous Cell Carcinoma of the Penis
【24h】

Predictors of Cancer-specific Mortality After Disease Recurrence in Patients with Squamous Cell Carcinoma of the Penis

机译:阴茎鳞状细胞癌患者疾病复发后癌症特异性死亡率预测

获取原文
获取原文并翻译 | 示例
           

摘要

Disease recurrence occurs frequently after surgical treatment for squamous cell carcinoma of the penis (SCCp). We sought to determine prognostic factors that influence cancer-specific mortality (CSM) after disease recurrence in patients with SCCp. We performed a retrospective analysis of 314 patients who experienced disease recurrence after surgical treatment for SCCp between 1949 and 2012. Competing risk regression analysis addressed factors associated with CSM after SCCp recurrence. Median time from surgery to disease recurrence was 10.5 mo (interquartile range [IQR]: 5.9-21.3). Of the recurrences, 165 (53%), 118 (38%), and 31 (9.9%) were local, regional, or distant, respectively. Within a median follow-up of 4.5 yr (IQR: 2.0-6.5), 108 patients died of SCCp and 41 patients died of causes other than SCCp. Shorter time to disease recurrence was found to be significantly associated with a higher risk of CSM (p = 0.0006). Lymph node metastasis at the time of initial treatment (subdistribution hazard ratio [SHR]: 1.96; 95% confidence interval [CI] 1.23- 3.11; p = 0.005) and regional recurrence (SHR: 4.14; 95% CI, 2.16-7.93; p< 0.0001) or distant recurrence (SHR: 5.75; 95% CI, 2.59-12.73; p < 0.0001) were associated with increased risk of CSM after disease recurrence. Inclusion of time to recurrence into risk stratification may help patient counseling and treatment planning.
机译:在阴茎鳞状细胞癌(SCCP)的外科治疗后经常发生疾病复发。我们试图确定在SCCP患者疾病复发后影响癌症特异性死亡率(CSM)的预后因素。我们对1949年至2012年间SCCP进行手术治疗后的314例疾病复发的314名患者进行了回顾性分析。竞争风险回归分析SCCP复发后CSM相关的因素。从手术到疾病复发的中位数是10.5 Mo(局部漫步范围[IQR]:5.9-21.3)。复发,165(53%),118(38%)和31(9.9%)分别为局部,区域或遥远。在4.5年的中间后续行动范围内(IQR:2.0-6.5),108名患者死于SCCP,41名患者死于SCCP以外的原因。发现疾病复发时间较短,与CSM的风险较高(P = 0.0006)显着相关。初始治疗时淋巴结转移(分区危险比[SHR]:1.96; 95%置信区间[CI] 1.23- 3.11; P = 0.005)和区域复发(SHR:4.14; 95%CI,2.16%CI; P <0.0001)或远程复发(SHR:5.75; 95%CI,2.59-12.73; P <0.0001)与疾病复发后CSM的风险增加有关。将时间融入危险分层可能有助于患者咨询和治疗计划。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号